<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7406B36D-18FA-4CAF-BE3B-AD773EB81BAA"><gtr:id>7406B36D-18FA-4CAF-BE3B-AD773EB81BAA</gtr:id><gtr:firstName>Heidrun</gtr:firstName><gtr:surname>Interthal</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700257"><gtr:id>F0D74F2A-3C30-4DA2-8BA2-5B40C8338B70</gtr:id><gtr:title>Repair of covalent protein-DNA complexes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700257</gtr:grantReference><gtr:abstractText>I am studying the repair of covalent topoisomerase-DNA complexes. A number of anti-cancer drugs that are in clinical use today induce the formation of such complexes. The resulting DNA strand breaks are particularly difficult to repair since a large protein, which is chemically linked to the DNA, covers the DNA end at the break. Unrepaired DNA double-strand breaks lead to cell death, especially in cells that are dividing rapidly, such as cancer cells. The DNA repair activity Tdp1 removes covalently trapped topoisomerase I from the DNA. Thus, a tandem drug regimen with a Tdp1 inhibitor and a drug that creates a substrate for Tdp1, e.g. the topoisomerase IB-specific anti-cancer drug camptothecin could potentiate the cytotoxicity and efficacy of both drugs. Therefore, I propose to search for drugs that inhibit Tdp1. 
A mutation in Tdp1 causes the neurodegenerative disorder SCAN1. I propose to identify the molecular mechanism of this disease using a mouse model. These experiments will contribute to understanding the relationship between DNA repair and neurodegeneration.
To apply my expertise with Tdp1 to another human health problem I propose to evaluate the suitability of Trypanosoma brucei Tdp1 as a drug target for anti-parasitic therapy to fight African sleeping sickness.</gtr:abstractText><gtr:technicalSummary>The goal of my research is to understand at the molecular and cellular level how cells repair the damage that occurs when enzymes become trapped in covalent complexes on DNA. A potentially lethal form of DNA damage occurs when a topoisomerase cleaves DNA and becomes trapped in the covalent topoisomerase-DNA reaction intermediate. These lesions are converted into more permanent DNA single- or double-strand breaks when encountered by the replication or transcription machinery. A number of clinically used anti-cancer drugs, such as the topo I-specific poison camptothecin (CPT) and the topo II specific drug etoposide, induce the formation of topoisomerase-DNA complexes. The cytotoxic effects of these drugs are directly related to the accumulation of such complexes. Pharmacological inhibition of the relevant DNA repair activities could synergistically potentiate the efficacy and cytotoxicity of both drugs. 

Therefore, I propose to identify and characterize the repair pathways for topoisomerase I- and topoisomerase II-DNA covalent complexes using a combination of cell biology, molecular biology, and biochemistry. Possible repair pathways could include endonucleolytic processing of covalent topoisomerase-linked DNA breaks or direct hydrolysis of the covalent topoisomerase-DNA linkage. The only repair activity for topoisomerase-DNA complexes identified so far is Tdp1, which specifically hydrolyzes the phosphodiester bond between topo I and the 3? end of the DNA. I propose to elucidate the mechanism and the cellular functions of Tdp1. More precisely, I will determine which modifications of stalled topo I are required before Tdp1 action and use TAP-tagging of Tdp1 to identify interacting proteins. Based on my in vitro studies of Tdp1 it is likely that it has additional roles in human cells. I propose to test these hypotheses in vivo. In parallel, I will evaluate the suitability of Trypanosoma brucei Tdp1 as a drug target to fight African sleeping sickness. 

A mutationn Tdp1 causes the hereditary neurodegenerative disorder SCAN1. I propose to elucidate the molecular mechanism of SCAN1 by using mouse Tdp1 knock out cell lines. I hypothesize that the SCAN1 phenotype is not caused by lack of Tdp1 activity, but rather by the property of the mutant protein to become covalently stalled on the DNA, thereby just replacing a stalled topo I. The outcome of these experiments will contribute to understanding the relationship between DNA repair and neurodegeneration. 

Finally, I propose to identify Tdp1 specific inhibitors using two complimentary approaches. We will use structure-based drug design and establish fluorescence-based high-throughput inhibitor screening procedures.</gtr:technicalSummary><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1007191</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Immunology and Infection Research</gtr:department><gtr:description>Trypanosoma brucei Tdp1</gtr:description><gtr:id>61FCD2C9-C810-484C-96FD-35F26200C65B</gtr:id><gtr:impact>To this end we have shown that TbTdp1 is involved in the repair of topoisomerase I-DNA adducts, similar to its role in mammalian cells. Based on a unique set of cell lines that we generated we were able to study Tdp1 mutants that informed our studies with human Tdp1.</gtr:impact><gtr:outcomeId>e5BPbAnP1pz-1</gtr:outcomeId><gtr:partnerContribution>Without Dr. Achim Schnaufer's expertise in working with T. brucei we would not have been able to start this project. He also provides the infrastructure and materials, such as strains and expression vectors, for working with bloodstream form trypanosomes. The project is discussed regularly.</gtr:partnerContribution><gtr:piContribution>We are investigating the role of the DNA repair protein Tdp1 in Trypanosoma brucei. Analogous to cancer therapy Tdp1 could be a potential drug target for anti parasite therapy to fight African Sleeping Sickness.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Site-specific crosslinking and mass spectrometry to map protein-DNA interactions</gtr:description><gtr:id>CE64DB1F-4061-4E46-AEB6-2364FFE1F02F</gtr:id><gtr:impact>This is an inter-disciplinary collaboration between the Institute of Cell Biology and the School of Chemistry at the University of Edinburgh. It has resulted in one publication (Anal Chem. 2015 Oct 6;87(19):9595-9. doi: 10.1021/acs.analchem.5b02047. Click chemistry generated model DNA-peptide heteroconjugates as tools for mass spectrometry.).</gtr:impact><gtr:outcomeId>56e072f84a8559.45767915-1</gtr:outcomeId><gtr:partnerContribution>Dr. Logan Mackay from the School of Chemistry provided all expertise, training, and equipment concerning the mass spectrometry aspect of the project.</gtr:partnerContribution><gtr:piContribution>My research group performed all experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Secondary School student work placement in my lab</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B324713C-FD06-4900-8670-27588EB6FB1E</gtr:id><gtr:impact>Secondary school students from Germany spent one week in the lab doing a small project. They reported back to their advanced Biology class on our research and their experience as a short term researcher.

First project was regarded a very successful and a second high school student came this year.</gtr:impact><gtr:outcomeId>ngK2P7FjstV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>UV cross-linking of nucleic acids to proteins in combination with mass spectrometry is a powerful technique to identify proteins, peptides, and the amino acids involved in intermolecular interactions within nucleic acid-protein complexes. However, the mass spectrometric identification of cross-linked nucleic acid-protein heteroconjugates in complex mixtures and MS/MS characterization of the specific sites of cross-linking is extremely challenging. As a tool for the optimization of sample preparation, ionization, fragmentation, and detection by mass spectrometry, novel synthetic DNA-peptide heteroconjugates were generated to act as mimics of UV cross-linked heteroconjugates. Click chemistry was employed to cross-link peptides to DNA oligonucleotides. These heteroconjugates were fully characterized by high resolution FTICR mass spectrometry and by collision-induced dissociation (CID) following nuclease P1 digestion of the DNA moiety to a single nucleotide monophosphate. This allowed the exact site of the cross-linking within the peptide to be unambiguously assigned. These synthetic DNA-peptide heteroconjugates have the potential to be of use for a variety of applications that involve DNA-peptide heteroconjugates.</gtr:description><gtr:id>59B42676-1EA6-4EEE-9E1F-D1B58A9D894A</gtr:id><gtr:impact>The development of these synthetic model DNA-peptide heteroconjugates enabled us to develop a protocol that led to the identification of specifc DNA-human Tdp1 interactions.</gtr:impact><gtr:outcomeId>56e07512d72599.72833382</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>click-chemistry generated DNA-peptide heteroconjugates as tools for mass spectrometry</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D4EFA254-5859-4B05-A808-5EC929E2FAA5</gtr:id><gtr:title>Structural basis for DNA 3'-end processing by human tyrosyl-DNA phosphodiesterase 1.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee849367c94e9e96895513bb0162172f"><gtr:id>ee849367c94e9e96895513bb0162172f</gtr:id><gtr:otherNames>Flett FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a748d588c76d8.15032129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC6DD255-36C8-4D3A-B507-58FA1245F6C1</gtr:id><gtr:title>Spinocerebellar ataxia with axonal neuropathy.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5caca4383e257bcfa7d625db70174f22"><gtr:id>5caca4383e257bcfa7d625db70174f22</gtr:id><gtr:otherNames>Walton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_15016_26_20687496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ACC6C81-9D2E-47C9-BE8D-F7358B9262A3</gtr:id><gtr:title>Separation of DNA oligonucleotides using denaturing urea PAGE.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7492f21938886f091c2f157dda2d0c1"><gtr:id>e7492f21938886f091c2f157dda2d0c1</gtr:id><gtr:otherNames>Flett F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_15016_26_23913292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E33F88E-B23A-495F-8AAA-19FB3D0B011D</gtr:id><gtr:title>Click chemistry generated model DNA-peptide heteroconjugates as tools for mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee849367c94e9e96895513bb0162172f"><gtr:id>ee849367c94e9e96895513bb0162172f</gtr:id><gtr:otherNames>Flett FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>56e0408d8f3996.72564180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>670DA7F8-10DB-499C-9F3E-A754B6F3F802</gtr:id><gtr:title>Differential EnzymaticO/O Labeling for the Detection of Cross-Linked Nucleic Acid-Protein Heteroconjugates.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee849367c94e9e96895513bb0162172f"><gtr:id>ee849367c94e9e96895513bb0162172f</gtr:id><gtr:otherNames>Flett FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>5a2fd796a9c2c6.24207452</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700257</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>